Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9329618 | Gynécologie Obstétrique & Fertilité | 2005 | 11 Pages |
Abstract
Positron emission tomography (PET) using fluorodeoxyglucose (FDG) is a new metabolic imaging modality that is becoming accessible in France. Many centers have been or will be equipped soon. The indications of PET-FDG have been established in various settings in some oncology pathologies such as lymphoma or lung cancer, but not in gynaecological and breast cancers. Therefore, we aimed to precise the interest of PET-FDG to detect, stage and restage the cancers of breast, ovary, cervix and uterus by reviewing the recent publications.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
D. Grahek, E. Barranger, E. Daraï, S. Uzan, J.-N. Talbot,